Clinical trial NCT05004259 - References

Hemolytic Anemia — The Safety of Repurposing Daratumumab for Relapsed or Refractory Autoimmune Antibody Mediated Hemolytic Anemia

Citation(s)

•   Birgens H, Frederiksen H, Hasselbalch HC, Rasmussen IH, Nielsen OJ, Kjeldsen L, Larsen H, Mourits-Andersen T, Plesner T, Ronnov-Jessen D, Vestergaard H, Klausen TW, Schollkopf C
  A phase III randomized trial comparing glucocorticoid monotherapy versus glucocorticoid and rituximab in patients with autoimmune haemolytic anaemia. Br J Haematol. 2013 Nov;163(3):393-9. doi: 10.1111/bjh.12541. Epub 2013 Aug 24.
•   Blennerhassett R, Sudini L, Gottlieb D, Bhattacharyya A
  Post-allogeneic transplant Evans syndrome successfully treated with daratumumab. Br J Haematol. 2019 Oct;187(2):e48-e51. doi: 10.1111/bjh.16171. Epub 2019 Aug 23. No abstract available.
•   Chapuy CI, Aguad MD, Nicholson RT, AuBuchon JP, Cohn CS, Delaney M, Fung MK, Unger M, Doshi P, Murphy MF, Dumont LJ, Kaufman RM; DARA-DTT Study Group* for the BEST Collaborative
  International validation of a dithiothreitol (DTT)-based method to resolve the daratumumab interference with blood compatibility testing. Transfusion. 2016 Dec;56(12):2964-2972. doi: 10.1111/trf.13789. Epub 2016 Sep 7.
•   Eaton WW, Rose NR, Kalaydjian A, Pedersen MG, Mortensen PB
  Epidemiology of autoimmune diseases in Denmark. J Autoimmun. 2007 Aug;29(1):1-9. doi: 10.1016/j.jaut.2007.05.002. Epub 2007 Jun 19.
•   Even-Or E, Naser Eddin A, Shadur B, Dinur Schejter Y, Najajreh M, Zelig O, Zaidman I, Stepensky P
  Successful treatment with daratumumab for post-HSCT refractory hemolytic anemia. Pediatr Blood Cancer. 2020 Jan;67(1):e28010. doi: 10.1002/pbc.28010. Epub 2019 Sep 22.
•   Go RS, Winters JL, Kay NE
  How I treat autoimmune hemolytic anemia. Blood. 2017 Jun 1;129(22):2971-2979. doi: 10.1182/blood-2016-11-693689. Epub 2017 Mar 30.
•   Hill QA, Hill A, Berentsen S
  Defining autoimmune hemolytic anemia: a systematic review of the terminology used for diagnosis and treatment. Blood Adv. 2019 Jun 25;3(12):1897-1906. doi: 10.1182/bloodadvances.2019000036.
•   Lechner K, Jager U
  How I treat autoimmune hemolytic anemias in adults. Blood. 2010 Sep 16;116(11):1831-8. doi: 10.1182/blood-2010-03-259325. Epub 2010 Jun 14.
•   Migdady Y, Ediriwickrema A, Jackson RP, Kadi W, Gupta R, Socola F, Arai S, Martin BA
  Successful treatment of thrombocytopenia with daratumumab after allogeneic transplant: a case report and literature review. Blood Adv. 2020 Mar 10;4(5):815-818. doi: 10.1182/bloodadvances.2019001215.
•   Reynaud Q, Durieu I, Dutertre M, Ledochowski S, Durupt S, Michallet AS, Vital-Durand D, Lega JC
  Efficacy and safety of rituximab in auto-immune hemolytic anemia: A meta-analysis of 21 studies. Autoimmun Rev. 2015 Apr;14(4):304-13. doi: 10.1016/j.autrev.2014.11.014. Epub 2014 Dec 9.
•   Schuetz C, Hoenig M, Moshous D, Weinstock C, Castelle M, Bendavid M, Shimano K, Tolbert V, Schulz AS, Dvorak CC
  Daratumumab in life-threatening autoimmune hemolytic anemia following hematopoietic stem cell transplantation. Blood Adv. 2018 Oct 9;2(19):2550-2553. doi: 10.1182/bloodadvances.2018020883.
•   Tolbert, Vanessa P
  , et al.
•   Zanella A, Barcellini W
  Treatment of autoimmune hemolytic anemias. Haematologica. 2014 Oct;99(10):1547-54. doi: 10.3324/haematol.2014.114561.

The Safety of Repurposing Daratumumab for Relapsed or Refractory Autoimmune Antibody Mediated Hemolytic Anemia

Details for clinical trial NCT05004259